• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

2 Minute Medicine Rewind August 11 – August 18, 2013

bys25qthea
August 18, 2013
in Cardiology, Chronic Disease, Infectious Disease, Oncology, Public Health, Urology, Weekly Rewinds
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

Image: PD 

In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. 

Long-Term Survival of Participants in the Prostate Cancer Prevention Trial

The Prostate Cancer Prevention Trial (PCPT), a randomly controlled trial conducted from 1994-2004involving 18,882 men randomized to receive either finasteride or placebo, demonstrated that finasteride reduced the relative risk of prostate cancer by 24.8% but showed a relative increase of 26.9% for the risk of high-grade prostate cancer. In this follow-up analysis, researchers collected data on the incidence of prostate cancer among PCPT patients for an additional year after the PCPT’s conclusion and looked at differences in all-cause and prostate-cancer mortality through 2011.  Finasteride reduced the overall risk of prostate cancer (10.5% vs. 14.9%, relative risk 0.70, 95% CI 0.65-0.76, P<0.001) and increased the risk of high-grade prostate cancer(3.5% vs. 3.0%,  relative risk 1.17, 95% CI 1.00-1.37, P=0.05). However, it had no significant effect on overall survival in prostate cancer patients after 18 years of follow-up (15-year survival 78.0% vs. 78.2%, HR 1.02, P=0.46).

Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial

Small trials have shown a decrease in the release of myocardial injury biomarkers after various cardiac procedures for patients who undergo remote ischemic precondition using short periods of induced ischemia followed by reperfusion.  In this randomized controlled trial, 329 patients undergoing triple-vessel coronary artery bypass surgery (CABG) were assigned to receive ischemic preconditioning or no preconditioning, with the primary outcome being perioperative concentrations of cardiac troponin I (cTnI) measured by the geometric mean area under the curve (AUC) in the first 72 hours after CABG.  The ratio of cTnI AUC in the intervention to control group was 0.83 (95% CI 0.70-0.97, P=0.022) in the intention-to-treat analysis and 0.79 (85% CI 0.66-0.94, P=0.001) in the per-protocol analysis.  All-cause mortality over 1.54 years was lower in the intervention group (ratio 0.27, 95% CI 0.08-0.98, P=0.046). Remote ischemic preconditioning appears to provide perioperative myocardial protection and significantly reduces the mortality of patients undergoing CABG.

The State of US Health, 1990-2010.  Burden of Diseases, Injuries, and Risk Factors

RELATED REPORTS

Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]

Unsweetened coffee consumption is associated with reduced risk of mortality

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

The report from the Global Burden of Disease 2010 study is a systematic analysis of the epidemiology of 291 disease and injuries in the US, with calculated outcomes being years of life lost due to premature mortality (YLLs), years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE).  Investigators found that US life expectancy increased from 75.2 years in 1990 to 78.2 years in 2010 with the HALE improving from 65.8 years to 68.1 years.  Diseases that caused the greatest YLLs were ischemic heart disease, lung cancer, stroke, chronic obstructive pulmonary disease, and road injury.  Conditions that caused the greatest YLDs were low back pain, major depressive disorder, other musculoskeletal disorders, neck pain, and anxiety disorders.  Among the 34 OECD countries, the US’s progress in improving population health was comparatively slower and its ranked dropped from 18 to 27 for death rate, 23 to 28 for YLL rate, 5 to 6 for YLD rate, 20-27 for life expectancy, and 14 to 26 for HALE.

Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO): a randomised trial

Fetuses with lower urinary tract obstruction (LUTO) have high perinatal and long-term mortality and morbidity.  Vesicoamniotic shunting has been proposed as a possible treatment.  In this randomized trial, 31 patients with singleton pregnancies complicated by LUTO were assigned to receive either vesicoamniotic shunting or conservative management with the primary outcome being survival of the baby to 28 days postnatally.  Of the 16 pregnancies that received the intervention, 8 neonates survived to 28 days compared to 4 of the 15 pregnancies that received conservative management (intention-to-treat relative risk 1.88, 95% CI 0.71-4.96, P=0.27; per-protocol relative risk 3.20, 95% CI 1.06-9.62, P=0.03).  This study was closed early because of poor recruitment and could not conclusively show a benefit.  Results trended towards increased survival in the intervention group, but there was still very high morbidity and mortality.

Faldaprevir and Deleobuvir for HCV Genotype 1 Infection

Because of the significant adverse effects associated with interferon, interferon-free regimens for the treatment of chronic hepatitis C virus (HCV) infection are highly desirable.  In this phase 2, randomized open-label trial, 362 patients were assigned to receive one of 5 different dosing regimens that included faldaprevir (a protease inhibitor) and deleobuvir (a nonnucleoside polymerase inhibitor) with ribavirin (named TID16W, TID28W, TID40W, or BID28W) or without ribavirin (named TID28W-NR).  The primary outcome was sustained virologic response 12 weeks after completing therapy.  In the non-ribavirin groups, the primary endpoint was met in 59%, 59%, 52%, and 69% of the patients for the TID16W, TID28W, TID40W, and BID28W groups respectively, compared with 39% of patients in the TID28W-NR group, with a statistically significant difference between the TID28W and TID28W-NR groups (P=0.03).  Faldaprevir combined with deleobuvir appears to be an effective interferon-free treatment for chronic HCV infection, demonstrating sustained virologic response 12 weeks after therapy completion for 52-69% of patients.

By Neal Yuan and David Ouyang

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: cancerprostate
Previous Post

The EINSTEIN-DVT trial: Rivaroxaban in acute deep-vein thrombosis [Classics Series]

Next Post

Difficulty diagnosing autism spectrum disorders in Latino children

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]

June 29, 2022
European data showed coffee consumption associated with lower mortality
Cardiology

Unsweetened coffee consumption is associated with reduced risk of mortality

June 21, 2022
#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
Parents desensitized with increasing exposure to movie violence/sex
Cardiology

Unmarried status associated with an increased risk of mortality in Asian populations

June 1, 2022
Next Post
Severe maternal childhood abuse associated with autism in offspring

Difficulty diagnosing autism spectrum disorders in Latino children

Quality improvement methods increase adherence to pediatric UTI guidelines

Urinary mRNA profiling accurately diagnoses rejection in kidney allografts

Healthy diet delays development, progression of chronic kidney disease in diabetics

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency
  • Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]
  • #VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.